Taysha Gene Therapies (TSHA) Return on Sales (2022 - 2025)
Historic Return on Sales for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to 14.92%.
- Taysha Gene Therapies' Return on Sales fell 16000.0% to 14.92% in Q3 2025 from the same period last year, while for Sep 2025 it was 14.92%, marking a year-over-year decrease of 67100.0%. This contributed to the annual value of 10.15% for FY2024, which is 53700.0% down from last year.
- Latest data reveals that Taysha Gene Therapies reported Return on Sales of 14.92% as of Q3 2025, which was down 16000.0% from 12.54% recorded in Q2 2025.
- Over the past 5 years, Taysha Gene Therapies' Return on Sales peaked at 74.86% during Q1 2022, and registered a low of 17.88% during Q2 2024.
- In the last 4 years, Taysha Gene Therapies' Return on Sales had a median value of 6.64% in 2024 and averaged 5.52%.
- Its Return on Sales has fluctuated over the past 5 years, first plummeted by -786100bps in 2023, then soared by 53400bps in 2025.
- Taysha Gene Therapies' Return on Sales (Quarter) stood at 42.2% in 2022, then tumbled by -110bps to 4.17% in 2023, then crashed by -116bps to 9.03% in 2024, then tumbled by -65bps to 14.92% in 2025.
- Its Return on Sales stands at 14.92% for Q3 2025, versus 12.54% for Q2 2025 and 8.74% for Q1 2025.